XML 46 R36.htm IDEA: XBRL DOCUMENT v3.19.2
Financial Instruments and Fair Value Measurements (Tables)
 6 Months Ended
Jun. 28, 2019
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

June 28,
2019

Quoted Prices in Active Markets for Identical Assets
(Level 1)

Significant Other Observable Inputs
(Level 2)

Significant Unobservable Inputs
(Level 3)
Assets:








Debt and equity securities held in rabbi trusts
$
35.4

 
$
25.6

 
$
9.8

 
$
—


 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Deferred compensation liabilities
$
45.4

 
$
—

 
$
45.4

 
$
—

Contingent consideration and acquired contingent liabilities
130.4

 
—

 
—

 
130.4


$
175.8

 
$
—

 
$
45.4

 
$
130.4

 
December 28,
2018
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Debt and equity securities held in rabbi trusts
$
33.1

 
$
22.4

 
$
10.7

 
$
—

 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Deferred compensation liabilities
$
38.5

 
$
—

 
$
38.5

 
$
—

Contingent consideration and acquired contingent liabilities
151.4

 
—

 
—

 
151.4

 
$
189.9

 
$
—

 
$
38.5

 
$
151.4
Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities The following table summarizes the fiscal 2019 activity for contingent consideration:
Balance as of December 28, 2018
$
151.4

Payments
(25.0
)
Accretion expense
1.7

Fair value adjustments
2.3

Balance as of June 28, 2019
$
130.4
Schedule of Carrying Amount and Fair Value of Long-term Debt The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period:

June 28, 2019

December 28, 2018

Carrying
Value

Fair
Value

Carrying
Value

Fair
Value
Level 1:
 
 
 
 
 
 
 
4.875% notes due April 2020
$
700.0

 
$
675.1

 
$
700.0

 
$
676.6

Variable-rate receivable securitization due July 2020
200.0

 
200.0

 
250.0

 
250.0

5.75% notes due August 2022
663.2

 
567.7

 
835.2

 
713.6

4.75% notes due April 2023
400.1

 
281.1

 
500.2

 
336.7

5.625% notes due October 2023
680.2

 
513.5

 
731.4

 
557.0

5.50% notes due April 2025
596.1

 
399.8

 
692.1

 
479.1

Revolving credit facility
405.0

 
405.0

 
220.0

 
220.0

Level 2:
 
 
 
 
 
 
 
9.50% debentures due May 2022
10.4

 
9.5

 
10.4

 
9.7

8.00% debentures due March 2023
4.4

 
3.7

 
4.4

 
3.8

Term loan due September 2024
1,524.7

 
1,365.8

 
1,613.8

 
1,472.4

Term loan due February 2025
404.6

 
363.3

 
597.0

 
548.0

Level 3:
 
 
 
 
 
 
 
Other
2.3

 
2.2

 
2.2

 
2.2

Total debt
$
5,591.0

 
$
4,786.7

 
$
6,156.7

 
$
5,269.1
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales:
 
Three Months Ended
 
Six Months Ended
 
June 28,
2019
 
June 29,
2018
 
June 28,
2019
 
June 29,
2018
CuraScript, Inc.
31.9
%
 
35.6
%
 
29.8
%
 
35.6
%
The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
 
June 28,
2019
 
December 28,
2018
AmerisourceBergen Corporation
27.7
%
 
25.7
%
McKesson Corporation
13.4
%
 
21.9
%
CuraScript, Inc.
15.7
%
 
13.1
%
The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales:

Three Months Ended
 
Six Months Ended

June 28,
2019
 
June 29,
2018
 
June 28,
2019
 
June 29,
2018
Acthar Gel
32.4
%
 
35.5
%
 
30.4
%
 
34.0
%
Inomax
17.0
%
 
15.9
%
 
18.0
%
 
17.1
%
Ofirmev
11.0
%
 
10.4
%
 
11.5
%
 
10.6
%